…
Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Amarantus Bioscience Holdings is a small-cap biotechnology company listed on the OTC Pink that develops therapeutic and diagnostic candidates for neurological and neurodegenerative disorders. Long-term growth drivers include progress through clinical and regulatory milestones, potential licensing or collaboration opportunities, and demographic trends increasing demand for relevant diagnostics and treatments, which may benefit shareholders if programs advance.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -4.76M | -10.20M | -0.63M | 18.38M | -10.58M |
| Net income | -4.76M | -10.20M | -0.63M | 18.38M | -10.58M |
| Selling general administrative | - | - | - | - | 3.04M |
| Gross profit | 0.10M | - | 0.07M | 20.00M | - |
| Ebit | -4.76M | -10.20M | -0.63M | 18.38M | -3.04M |
| Ebitda | -4.53M | -9.96M | -0.42M | 18.55M | - |
| Depreciation and amortization | 0.23M | 0.24M | 0.21M | 0.17M | - |
| Operating income | -0.27M | -0.15M | -0.63M | 18.33M | -3.04M |
| Other operating expenses | 0.36M | 0.15M | 0.70M | 1.67M | - |
| Interest expense | - | - | - | - | 0.00M |
| Income tax expense | -0.23M | - | - | - | - |
| Total revenue | 0.10M | - | 0.07M | 20.00M | - |
| Total operating expenses | 0.36M | 0.15M | 0.70M | 1.67M | 3.04M |
| Total other income expense net | -4.49M | -10.05M | 0.00M | 0.05M | -7.54M |
| Net income from continuing ops | - | - | - | - | -10.58M |
| Net income applicable to common shares | - | - | - | - | -10.58M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 10.21M | 14.71M | 24.87M | 24.79M | 3.48M |
| Intangible assets | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Other current assets | 0.03M | 0.03M | 0.03M | 0.03M | - |
| Total liab | 34.87M | 34.63M | 34.36M | 33.74M | 31.39M |
| Total stockholder equity | -24.67M | -19.93M | -9.48M | -8.96M | -30.76M |
| Other current liab | 0.42M | -15.44M | -15.16M | -14.60M | - |
| Common stock | 0.29M | 0.28M | 0.27M | 0.26M | 0.22M |
| Retained earnings | -106.47M | -101.65M | -91.25M | -90.62M | -115.60M |
| Cash | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Total current liabilities | 34.87M | 34.63M | 34.36M | 33.74M | 31.39M |
| Net debt | 19.14M | 19.19M | 19.20M | 19.14M | - |
| Short term debt | 19.14M | 19.19M | 19.20M | 19.14M | - |
| Short long term debt total | 19.14M | 19.19M | 19.20M | 19.14M | - |
| Other stockholder equity | 80.28M | 80.19M | 80.23M | 80.11M | - |
| Total current assets | 0.03M | 0.03M | 0.03M | 0.03M | 0.75M |
| Long term investments | - | - | - | - | 2.73M |
| Net tangible assets | - | - | - | - | -30.77M |
| Net receivables | - | - | - | - | 0.03M |
| Accounts payable | 15.31M | 15.44M | 15.16M | 14.60M | 12.73M |
| Accumulated other comprehensive income | -0.29M | -0.28M | -0.27M | -0.26M | - |
| Non current assets total | 10.18M | 14.68M | 24.84M | 24.75M | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | - | - | - | - | 6.07M |
| Change to liabilities | - | - | - | - | 0.70M |
| Total cashflows from investing activities | 4.50M | 9.97M | -0.08M | -2.03M | 6.07M |
| Net borrowings | - | - | - | - | 7.89M |
| Total cash from financing activities | - | -0.05M | 0.16M | 1.01M | -4.33M |
| Change to operating activities | - | - | - | - | 0.57M |
| Net income | -4.76M | -10.20M | -0.63M | 18.38M | -10.58M |
| Change in cash | -0.00M | 0.00M | -0.00M | -0.00M | -0.05M |
| Begin period cash flow | 0.00M | 0.00M | 0.00M | 0.00M | - |
| End period cash flow | - | 0.00M | 0.00M | 0.00M | - |
| Total cash from operating activities | -4.50M | -9.93M | -0.08M | 1.02M | -1.80M |
| Other cashflows from investing activities | 4.50M | 9.97M | -0.08M | - | - |
| Change to account receivables | 0.06M | 0.21M | 0.07M | - | - |
| Other cashflows from financing activities | 4.50M | -0.05M | 0.09M | 0.06M | -2.96M |
| Change to netincome | - | - | - | - | 7.52M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.24M | 0.27M | 0.55M | -17.36M | - |
| Other non cash items | 0.02M | -0.27M | -0.55M | -0.72M | - |
| Free cash flow | -4.50M | -9.93M | -0.08M | 1.02M | - |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| AMBS Amarantus Bioscience Holdings Inc |
- -% |
0.00 | - | - | - | 53.19 | -0.40 |
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.
| Name | Title | Year Born |
|---|---|---|
| Mr. Gerald E. Commissiong | CEO, Pres & Director | 1983 |
| Dr. John Wesley Commissiong | Chief Scientific Officer, Director & Member of Scientific Advisory Board | 1945 |
| Mr. Robert Lewis Harris | Compliance Officer & Director | 1944 |
| Dr. Elise Brownell M.S., Ph.D. | Sr. VP of Operations & Project Management | NA |
| Aimee Boutcher | Director of Investor Relations | NA |
| Dr. Ravi Kiron | Sr. VP of Bus. Devel. | 1960 |
| Dr. Paula T. Trzepacz M.D. | Chief Medical Advisor to Elto Pharma and Breakthrough Diagnostics | NA |
| Dr. Brian E. Harvey | Chief Regulatory Advisor & Member of Board of Advisors | NA |
| Dr. Richard Kagan M.D. | Chief Medical Advisor to Cutanogen Corp. | NA |
| Dr. Owen Garrick | Corp. Advisor | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.